Rejected from Nature Immunology? The 7 Best Journals to Submit Next

• "The immunological mechanism is not sufficiently novel.": You showed that blocking pathway X improves immune response Y. But the pathway and the response were both known. Nature Immunology wants surprises, not confirmations, even well-executed ones.

• "The paper is primarily a disease study.": Your autoimmune disease model is sophisticated, but the immune insight is incremental. The paper tells us more about the disease than about the immune system. For Nature Immunology, the immunology must be the star, not the supporting cast.

• "The findings are of specialist interest.": Your paper advances a specific corner of mucosal immunology or NK cell biology, but the implications don't extend to immunologists working in other areas. Nature Immunology wants cross-subfield relevance.

• "The work is too descriptive.": You profiled immune cells in a new context (a tissue, a disease, a developmental stage) using scRNA-seq or CyTOF, but the paper doesn't go beyond cataloging to explain mechanism. Atlas papers without functional follow-up face desk rejection at Nature Immunology.

Nature Immunology editors can transfer manuscripts to:

• Nature Communications (IF ~16) - Broad scope, any immunology topic- Communications Biology (IF ~5) - Solid immunobiology- Nature Medicine (IF ~50) - If the clinical/disease implications are strongA transfer to Nature Communications is common for immunology papers that are technically strong but didn't meet Nature Immunology's "fundamental insight" threshold.

Before choosing your next journal, a Nature Immunology manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

• Desk-rejected for "too disease-focused"?: Go to JCI (if the disease mechanism is the core), Immunity (if the immune mechanism is novel despite the disease context), or Science Immunology (if there's a translational bridge).

• Desk-rejected for "too specialized"?: JEM accepts niche immunological findings. PNAS is strong for well-executed specialized work. Frontiers in Immunology for rapid publication.

• Desk-rejected for "descriptive without mechanism"?: If you can add functional experiments, do so before resubmitting anywhere. If the descriptive data is the paper, try PNAS (which values complete descriptions) or Frontiers in Immunology.

• Rejected after peer review?: Fix reviewer concerns. Immunity and JEM share reviewers with Nature Immunology. Address the feedback before resubmitting.

• Don't add a superficial mechanism: If Nature Immunology wanted mechanistic depth and you added two knockdown experiments, that won't satisfy Immunity or JEM either. Either do the mechanism properly or submit to a journal that values your descriptive data.

• Reframe for the new audience: Immunity readers expect Cell Press-style comprehensive stories. JEM readers value experimental rigor. JCI readers want disease relevance. Adjust your paper accordingly.

• Update your scRNA-seq analysis: If your paper is atlas-based, every immunology journal in 2026 expects standardized analysis pipelines, publicly deposited data, and reproducible computational workflows. Ensure these are in order.

Immunity (published by Cell Press) is Nature Immunology's most direct competitor. Both journals want fundamental immunological insight, and both are similarly selective. The difference is editorial tradition: Nature Immunology follows the Nature portfolio style (concise papers with strong figures), while Immunity follows the Cell Press style (more comprehensive stories with extensive supplementary data). Immunity is also slightly more receptive to disease-oriented immunology than Nature Immunology, provided the immunological mechanism is novel. If Nature Immunology said your paper was "too disease-focused," Immunity may find the disease context a strength rather than a weakness.

Best for: Fundamental immunology papers where Nature Immunology's rejection was about scope or editorial fit, not quality. Papers combining immune mechanism with disease relevance.

JEM is one of the oldest biomedical journals and has a strong tradition in immunology. The journal publishes broadly across experimental medicine but has particular strength in immunology, infectious disease, and cancer biology. JEM is published by Rockefeller University Press and has an academic editor model. Reviews tend to be thorough and constructive. The journal values mechanistic rigor and reproducibility. If Nature Immunology rejected your paper for being "too specialized," JEM may be more tolerant of niche immunological findings.

Best for: Mechanistic immunology, infectious disease immunology, tumor immunology, and immunology papers with strong experimental depth.

Science Immunology is the AAAS immunology journal and publishes cross-disciplinary immunology research. The journal leans slightly more translational than Nature Immunology and publishes more human immunology and clinical immunology alongside fundamental work. If your paper bridges basic immunology with clinical or translational applications, Science Immunology may appreciate that bridge more than Nature Immunology did. The journal also benefits from the Science editorial network, and rejected Science papers sometimes land here via transfer.

Best for: Translational immunology, human immune system studies, vaccine immunology, and immunology with clinical applications.

For immunology papers with a clear disease focus, JCI is an excellent target. The journal wants mechanistic insight into how diseases work, and the immune system is the mechanism for many diseases. Where Nature Immunology finds disease-focused immunology "too applied," JCI considers it core to their mission. JCI publishes excellent autoimmunity research, immunodeficiency studies, and immune-mediated disease mechanisms. If your paper explains why an immune process goes wrong in disease, JCI is a natural fit.

Best for: Autoimmune disease mechanisms, immunodeficiency studies, immune-mediated disease pathology, host-pathogen interaction mechanisms.

For immunology papers that are clearly good science but didn't meet Nature Immunology's fundamental-insight bar, Nature Communications provides a broad-scope home with a ~14% acceptance rate. The journal publishes immunology papers regularly and doesn't demand the "change how immunologists think" novelty threshold.

Best for: Solid immunology papers that fell below Nature Immunology's impact bar. Interdisciplinary immunology work.

PNAS publishes across all of science, including a substantial volume of immunology research. The journal values rigor and completeness without requiring the transformative novelty Nature Immunology demands. A thorough immunological characterization with proper controls and quantification can succeed at PNAS even if the finding is expected. PNAS is also strong for comparative immunology, evolutionary immunology, and computational immunology, subfields that Nature Immunology rarely covers.

Best for: Rigorous immunology across all subfields, comparative and evolutionary immunology, computational immunology, well-executed studies that advance understanding without being transformative.

Frontiers in Immunology has one of the highest acceptance rates (~40%) among immunology journals with a reasonable impact factor (~5). For papers that are technically sound and advance the field, even modestly, Frontiers provides rapid publication and broad open-access reach. The journal uses a collaborative review model where reviewers and authors work together to improve the manuscript. This produces a less adversarial review experience than traditional journals.

Best for: Sound immunology research that didn't clear the bars at top-tier journals. Rapid publication needs. Early-career researchers building a publication record.

• How to choose a journal for your paper
• Signs your paper is not ready to submit
• What pre-submission peer review includes

Before you resubmit, run your manuscript through a manuscript scope and readiness check to check fit, structure, and editorial risk before the next submission.

In our pre-submission review work with manuscripts targeting Nature Immunology, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Mechanism already established in the immunology literature. Nature Immunology publishes discoveries that rewrite immunological understanding, not papers that validate established mechanisms in additional contexts. We see this failure as the most common pattern in Nature Immunology desk rejections we review: papers demonstrating that a known cytokine, transcription factor, or signaling pathway operates as expected in a new immune cell subset or disease context, without revealing something unexpected about how the immune system works. In our review of Nature Immunology submissions, we find that editors consistently require the immunological principle to be genuinely new, not just the cell type or disease application.

Disease study framed as immunology study without identifying the immunological mechanism. Nature Immunology is an immunology journal, not a disease biology journal. Papers characterizing the immune contexture of a tumor, the immune response to a pathogen, or immune cell infiltrates in an inflammatory disease without mechanistically revealing how the immune system makes its decisions face consistent scope concerns. We see this pattern in Nature Immunology submissions we review present immunological correlates of disease without mechanistically explaining the regulatory logic behind them.

Descriptive profiling of immune populations without functional validation. Mass cytometry, single-cell RNA-seq, and spatial transcriptomics data describing immune cell populations in a disease context do not meet Nature Immunology's bar without functional experiments establishing what those populations actually do. We see this pattern in Nature Immunology submissions we review: comprehensive profiling studies identifying new immune cell states or population dynamics where the functional significance of the described populations is not established.

Findings primarily of interest to immunologists working in one narrow disease area. Nature Immunology serves all of immunology as a single readership. Papers revealing mechanisms specific to one autoimmune condition, one tumor type, or one pathogen without broader immunological principles face desk concerns about scope. The finding needs to teach something about how immunity works that immunologists outside the specific disease area would find instructive.

SciRev community data for Nature Immunology confirms desk decisions typically within 1-2 weeks, consistent with the Nature Portfolio editorial cadence across its specialist journals.